MILFORD, Mass., Aug. 18, 2011 /PRNewswire/ — PLC Systems Inc.
(OTCBB: PLCSF), a company focused on innovative medical device
technologies, today announced that final results from the
REMEDIAL II investigator-sponsored clinical trial of
RenalGuard® in Italy have been published on-line in
Circulation, a peer-reviewed journal of the American Heart
Association with a distribution of 23,900 worldwide, and will
appear in the September 2011 issue of the publication. The
results from this trial showed that RenalGuard is superior to the
current standard of care at preventing Contrast-Induced Nephropathy
(CIN) and in-hospital dialysis in high-risk patients undergoing
certain imaging procedures.
In this trial, the investigators discovered that patients
treated with RenalGuard and N-acetylcysteine (NAC) developed CIN, a
serious and potentially fatal condition, at a much lower rate than
patients in the control group who were treated with an infusion of
sodium bicarbonate and NAC. Sodium bicarbonate plus NAC remains the
current standard of care for the prevention of CIN in many
healthcare institutions worldwide. The results provided strong
scientific data that RenalGuard Therapy® is superior to sodium
bicarbonate and N-acetylcysteine in preventing contrast-induced
acute kidney injury (CI-AKI) in high-risk patients.
Mark R. Tauscher, President and Chief Executive Officer of PLC
Systems, said, “The positive results of the REMEDIAL II clinical
trial demonstrate with scientifically significant findings that
RenalGuard is a superior approach to reducing the incidence of CIN
in high-risk patients. This is another important proof point for
RenalGuard and for PLC, and we’re delighted that these results have
been favorably evaluated by Circulation‘s advisory
boar
‘/>”/>